Our observations point to anti-tumor immunity as a major mechanism of action of anti-HER2 antibodies in primary HER2-positive breast cancer patients with NK cell-rich tumors and provide the rationale for investigating combinatorial approaches with immunotherapy in those patients. The gene discussed is ERBB2; the disease is breast carcinoma.